143 related articles for article (PubMed ID: 37068273)
1. Oral Fluvoxamine With Inhaled Budesonide for Treatment of Early-Onset COVID-19 : A Randomized Platform Trial.
Reis G; Dos Santos Moreira Silva EA; Medeiros Silva DC; Thabane L; de Souza Campos VH; Ferreira TS; Quirino Dos Santos CV; Ribeiro Nogueira AM; Figueiredo Guimaraes Almeida AP; Cançado Monteiro Savassi L; de Figueiredo Neto AD; Bitarães C; Cruz Milagres A; Diniz Callegari E; Campos Simplicio MI; Barra Ribeiro L; Oliveira R; Harari O; Wilson LA; Forrest JI; Ruton H; Sprague S; McKay P; Guo CM; Guyatt GH; Rayner CR; Boulware DR; Ezer N; Lee TC; McDonald EG; Bafadhel M; Butler C; Rodrigues Silva J; Dybul M; Mills EJ;
Ann Intern Med; 2023 May; 176(5):667-675. PubMed ID: 37068273
[TBL] [Abstract][Full Text] [Related]
2. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial.
Reis G; Dos Santos Moreira-Silva EA; Silva DCM; Thabane L; Milagres AC; Ferreira TS; Dos Santos CVQ; de Souza Campos VH; Nogueira AMR; de Almeida APFG; Callegari ED; de Figueiredo Neto AD; Savassi LCM; Simplicio MIC; Ribeiro LB; Oliveira R; Harari O; Forrest JI; Ruton H; Sprague S; McKay P; Glushchenko AV; Rayner CR; Lenze EJ; Reiersen AM; Guyatt GH; Mills EJ;
Lancet Glob Health; 2022 Jan; 10(1):e42-e51. PubMed ID: 34717820
[TBL] [Abstract][Full Text] [Related]
3. Effect of Fluvoxamine vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: A Randomized Clinical Trial.
McCarthy MW; Naggie S; Boulware DR; Lindsell CJ; Stewart TG; Felker GM; Jayaweera D; Sulkowski M; Gentile N; Bramante C; Singh U; Dolor RJ; Ruiz-Unger J; Wilson S; DeLong A; Remaly A; Wilder R; Collins S; Dunsmore SE; Adam SJ; Thicklin F; Hanna G; Ginde AA; Castro M; McTigue K; Shenkman E; Hernandez AF;
JAMA; 2023 Jan; 329(4):296-305. PubMed ID: 36633838
[TBL] [Abstract][Full Text] [Related]
4. Higher-Dose Fluvoxamine and Time to Sustained Recovery in Outpatients With COVID-19: The ACTIV-6 Randomized Clinical Trial.
Stewart TG; Rebolledo PA; Mourad A; Lindsell CJ; Boulware DR; McCarthy MW; Thicklin F; Garcia Del Sol IT; Bramante CT; Lenert LA; Lim S; Williamson JC; Cardona OQ; Scott J; Schwasinger-Schmidt T; Ginde AA; Castro M; Jayaweera D; Sulkowski M; Gentile N; McTigue K; Felker GM; DeLong A; Wilder R; Rothman RL; Collins S; Dunsmore SE; Adam SJ; Hanna GJ; Shenkman E; Hernandez AF; Naggie S;
JAMA; 2023 Dec; 330(24):2354-2363. PubMed ID: 37976072
[TBL] [Abstract][Full Text] [Related]
5. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
6. Effect of Early Treatment with Ivermectin among Patients with Covid-19.
Reis G; Silva EASM; Silva DCM; Thabane L; Milagres AC; Ferreira TS; Dos Santos CVQ; Campos VHS; Nogueira AMR; de Almeida APFG; Callegari ED; Neto ADF; Savassi LCM; Simplicio MIC; Ribeiro LB; Oliveira R; Harari O; Forrest JI; Ruton H; Sprague S; McKay P; Guo CM; Rowland-Yeo K; Guyatt GH; Boulware DR; Rayner CR; Mills EJ;
N Engl J Med; 2022 May; 386(18):1721-1731. PubMed ID: 35353979
[TBL] [Abstract][Full Text] [Related]
7. Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial.
Yu LM; Bafadhel M; Dorward J; Hayward G; Saville BR; Gbinigie O; Van Hecke O; Ogburn E; Evans PH; Thomas NPB; Patel MG; Richards D; Berry N; Detry MA; Saunders C; Fitzgerald M; Harris V; Shanyinde M; de Lusignan S; Andersson MI; Barnes PJ; Russell REK; Nicolau DV; Ramakrishnan S; Hobbs FDR; Butler CC;
Lancet; 2021 Sep; 398(10303):843-855. PubMed ID: 34388395
[TBL] [Abstract][Full Text] [Related]
8. Early Treatment with Pegylated Interferon Lambda for Covid-19.
Reis G; Moreira Silva EAS; Medeiros Silva DC; Thabane L; Campos VHS; Ferreira TS; Santos CVQ; Nogueira AMR; Almeida APFG; Savassi LCM; Figueiredo-Neto AD; Dias ACF; Freire Júnior AM; Bitarães C; Milagres AC; Callegari ED; Simplicio MIC; Ribeiro LB; Oliveira R; Harari O; Wilson LA; Forrest JI; Ruton H; Sprague S; McKay P; Guo CM; Limbrick-Oldfield EH; Kanters S; Guyatt GH; Rayner CR; Kandel C; Biondi MJ; Kozak R; Hansen B; Zahoor MA; Arora P; Hislop C; Choong I; Feld JJ; Mills EJ; Glenn JS;
N Engl J Med; 2023 Feb; 388(6):518-528. PubMed ID: 36780676
[TBL] [Abstract][Full Text] [Related]
9. Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial.
Bramante CT; Buse JB; Liebovitz DM; Nicklas JM; Puskarich MA; Cohen K; Belani HK; Anderson BJ; Huling JD; Tignanelli CJ; Thompson JL; Pullen M; Wirtz EL; Siegel LK; Proper JL; Odde DJ; Klatt NR; Sherwood NE; Lindberg SM; Karger AB; Beckman KB; Erickson SM; Fenno SL; Hartman KM; Rose MR; Mehta T; Patel B; Griffiths G; Bhat NS; Murray TA; Boulware DR;
Lancet Infect Dis; 2023 Oct; 23(10):1119-1129. PubMed ID: 37302406
[TBL] [Abstract][Full Text] [Related]
10. Early antiviral treatment in outpatients with COVID-19 (FLARE): a structured summary of a study protocol for a randomised controlled trial.
Brown LK; Freemantle N; Breuer J; Dehbi HM; Chowdhury K; Jones G; Ikeji F; Ndoutoumou A; Santhirakumar K; Longley N; Checkley AM; Standing JF; Lowe DM
Trials; 2021 Mar; 22(1):193. PubMed ID: 33685502
[TBL] [Abstract][Full Text] [Related]
11. Effect of Higher-Dose Fluvoxamine vs Placebo on Time to Sustained Recovery in Outpatients with Mild to Moderate COVID-19: A Randomized Clinical Trial.
; Naggie S
medRxiv; 2023 Sep; ():. PubMed ID: 37745371
[TBL] [Abstract][Full Text] [Related]
12. Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial.
Ramakrishnan S; Nicolau DV; Langford B; Mahdi M; Jeffers H; Mwasuku C; Krassowska K; Fox R; Binnian I; Glover V; Bright S; Butler C; Cane JL; Halner A; Matthews PC; Donnelly LE; Simpson JL; Baker JR; Fadai NT; Peterson S; Bengtsson T; Barnes PJ; Russell REK; Bafadhel M
Lancet Respir Med; 2021 Jul; 9(7):763-772. PubMed ID: 33844996
[TBL] [Abstract][Full Text] [Related]
13. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
[TBL] [Abstract][Full Text] [Related]
14. Randomized clinical trial to compare the efficacy of ivermectin versus placebo to negativize nasopharyngeal PCR in patients with early COVID-19 in Peru (SAINT-Peru): a structured summary of a study protocol for randomized controlled trial.
Garcia PJ; Mundaca H; Ugarte-Gil C; Leon P; Malaga G; Chaccour C; Carcamo CP
Trials; 2021 Apr; 22(1):262. PubMed ID: 33836826
[TBL] [Abstract][Full Text] [Related]
15. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.
Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M
Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796
[TBL] [Abstract][Full Text] [Related]
16. Fluvoxamine for Outpatient Treatment of COVID-19: A Decentralized, Placebo-controlled, Randomized, Platform Clinical Trial.
McCarthy MW; Naggie S; Boulware DR; Lindsell CJ; Stewart TG; Felker GM; Jayaweera D; Sulkowski M; Gentile N; Bramante C; Singh U; Dolor RJ; Ruiz-Unger J; Wilson S; DeLong A; Remaly A; Wilder R; Collins S; Dunsmore SE; Adam SJ; Thicklin F; Hanna G; Ginde AA; Castro M; McTigue K; Shenkman E; Hernandez AF;
medRxiv; 2022 Nov; ():. PubMed ID: 36299427
[TBL] [Abstract][Full Text] [Related]
17. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
18. Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19: A Randomized Clinical Trial.
Lenze EJ; Mattar C; Zorumski CF; Stevens A; Schweiger J; Nicol GE; Miller JP; Yang L; Yingling M; Avidan MS; Reiersen AM
JAMA; 2020 Dec; 324(22):2292-2300. PubMed ID: 33180097
[TBL] [Abstract][Full Text] [Related]
19. Inhaled Budesonide for COVID-19 in People at Higher Risk of Complications in the Community: The UK National Community Randomi.
Hobbs R; Gbinigie O; Ogburn E; Yu LM; van Hecke O; Dorward J; Butler C; Saville B
Ann Fam Med; 2023 Jan; 21(21 Suppl 1):. PubMed ID: 36944089
[TBL] [Abstract][Full Text] [Related]
20. Hydroxychloroquine in the treatment of adult patients with Covid-19 infection in a primary care setting (LIBERTY): A structured summary of a study protocol for a randomised controlled trial.
Vainio PJ; Hietasalo P; Koivisto AL; Kääriäinen S; Turunen J; Virtala M; Vuorinen J; Scheinin M
Trials; 2021 Jan; 22(1):44. PubMed ID: 33430933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
